Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market indomethacin extended release capsules used in treating painful and inflammatory conditions such as arthritis.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 75 mg, it said in a BSE filing.
It will manufacture the drug at the Moraiya facility in Ahmedabad.
Zydus Cadila said it has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of the company's listed entity Cadila Healthcare were trading 2.70 per cent down at Rs 461.50 per scrip on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)